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Abstract
Background: Thyrotoxicosis is more frequent in postmenopausal women than in the general population, effectively accelerating bone turnover. 
Interleukin-6 has been shown to be involved in the pathogenesis of bone disorders. Thus, the aim of the present study was to assess the role 
of IL-6 and its soluble receptor in the pathogenesis of thyrotoxicosis-related disturbances of bone turnover in oestrogen-deficient women. 
Material and methods: The study was carried out in 40 subjects with toxic nodular goitre in three groups: Group 1 — 13 premenopausal 
females, mean age 36 ± 15 years (PremTxÆPremEu); Group 2 — 12 postmenopausal females, mean age 66 ± 14 years (PostTxÆPostEu); 
and Group 3 — 15 males, mean age 45 ± 21 years (MTxÆMEu). Overt thyrotoxicosis and euthyreosis after treatment with thyrostatics 
were confirmed by thyrotropin, free thyroxine and free triiodothyronin concentrations. Serum levels of bone turnover markers: TRACP5b 
and osteocalcin as well as serum IL-6 and IL-6sR were determined using ELISA kits. 
Results: TRACP5b/osteocalcin quotient was significantly elevated in the PostTx females compared to the PremTx women (p < 0.02). There 
was a positive correlation between serum TRACP5b and osteocalcin in the studied patients (R = 0.45, p < 0.001). Levels of serum IL-6 val-
ues were significantly elevated in PostTx: 3.0 (2.14–6.40) and MTx: 2.24 (1.60–5.10), compared to PremTx females: 1.39 (0.96–2.14) (p < 0.01 
and p < 0.05 respectively). There were significant positive correlations between IL-6 and IL-6sR concentrations (R = 0.22, p < 0.05) and 
between IL-6sR and TRACP5b serum levels (R = 0.23, p < 0.05). 
Conclusions: The results of our study suggest that interleukin-6 plays a considerable role in the pathogenesis of thyrotoxicosis-related 
disturbances of bone turnover in oestrogen-deficient women. (Pol J Endocrinol 2011; 62 (4): 299–302)
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Streszczenie
Wstęp: Nadczynność tarczycy występuje częściej u kobiet po menopauzie w porównaniu z populacją ogólną, skutecznie przyspieszając obrót 
kostny. Wykazano, że interleukina 6 (IL-6) odgrywa istotną rolę w regulacji obrotu kostnego. Uwzględniając ten fakt, celem obecnej pracy była próba 
oceny roli IL-6 i jej rozpuszczalnego receptora w patogenezie zaburzeń obrotu kostnego w przebiegu tyreotoksykozy u kobiet po menopauzie. 
Materiał i metody: Badanie przeprowadzono u 40 osób z nadczynnym wolem guzkowym w 3 grupach: 1 — 13 kobiet przed menopauzą 
w wieku 36 ± 15 lat (PremTxÆPremEu), 2 — 12 kobiet po menopauzie w wieku 66 ± 14 lat (PostTxÆPostEu) i 3 — 15 mężczyzn w wieku 
45 ± 21 lat (MTxÆMEu). Stan czynnościowy tarczycy potwierdzono oznaczeniem TSH, fT3 i fT4 w surowicy. Markery obrotu kostnego: 
TRACP5b i osteokalcyna oraz IL-6 i IL-6sR w surowicy, oznaczono zestawami ELISA. 
Wyniki: Iloraz TRACP5b/osteokalcyna był istotnie zwiększony u kobiet PostTx w porównaniu z grupą PremTx (p < 0,02). Stwierdzono 
dodatnią korelację między TRACP5b i osteokalcyną (R = 0,45, p < 0,001). Stężenie IL-6 było istotnie zwiększone w grupie PostTx: 3,0 
(2,14–6,40) i MTx: 2,24 (1,60–5,10) w porównaniu z odnotowanym u kobiet z grupy PremTx: 1,39 (0,96–2,14) (odpowiednio: p < 0,01 i p < 0,05). 
Wykazano istotną dodatnią korelację pomiędzy IL-6 i IL-6sR (R = 0,22, p < 0,05) oraz pomiędzy IL-6sR i TRACP5b (R = 0,23, p < 0,05). 
Wnioski: Podsumowując, wyniki obecnej pracy wskazują, że IL-6 odgrywa ważną rolę w patogenezie zaburzeń obrotu kostnego w prze-
biegu tyreotoksykozy u kobiet po menopauzie. (Endokrynol Pol 2011; 62 (4): 299–302)
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Introduction
The early years of the menopause are usually charac-
terised by a loss of bone mass that leads to reduced 
skeletal strength and increased susceptibility to frac-
tures. Thyrotoxicosis is more frequent in women of 
postmenopausal age than in the general population, 
effectively accelerating bone turnover. In thyrotoxi-
cosis, the duration of remodelling cycles is reduced, 
with maintained duration of resorption and shortened 
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formation, resulting in a loss of about 10% of mineral-
ised bone per cycle [1]. 
Oestrogen depletion in the menopause is accompa-
nied by an increased production of osteotrophic factors, 
such as interleukin-1 (IL-1), IL-6 and tumour necrosis 
factor [2, 3]. Those cytokines stimulate the differentia-
tion of myeloid precursor cells into osteoclasts, cells that 
are responsible for bone resorption [4]. 
Interleukin-6 has been shown to be involved in the 
pathogenesis of several bone diseases characterised by 
a negative balance between bone resorption and for-
mation, such as Paget’s disease, renal osteodystrophy 
and postmenopausal osteoporosis [5–7]. Moreover, in 
ovariectomised mice, IL-6 appeared to be crucial in bone 
turnover acceleration and a selective inhibitor of IL-6 
activity has been documented to suppress bone mass 
reduction [8, 9]. Recently, we have seen experimental 
data suggesting an important role of IL-6 in thyrotoxi-
cosis-related disturbances in bone turnover [10]. 
Interleukin-6 exerts its full effect through binding 
to both of its glycoprotein receptors present on target 
cells: IL-6R and gp130. A complex of IL-6 and a soluble 
form of IL-6R (IL-6sR) cleaved from the cell membrane 
may connect to membrane gp130 that leads to biologi-
cal action [11]. 
This current study was an attempt to assess the role 
of IL-6 and its soluble receptor in the pathogenesis of 
thyrotoxicosis-related disturbances of bone turnover in 
oestrogen-deficient women. 
Material and methods 
The study was carried out in forty subjects with toxic 
nodular goiter divided into three groups:
Group 1 — 13 premenopausal females, mean age 36 ± 15 
years (PremTxÆPremEu);
Group 2 — 12 postmenopausal females, mean age 
66 ± 14 years (PostTxÆPostEu);
Group 3 — 15 males, mean age 45 ± 21 years (MTxÆMEu). 
Overt thyrotoxicosis and euthyreosis after treatment 
with thyrostatics was confirmed by thyrotropin, free 
thyroxine and free triiodothyronin concentrations. No 
acute infections were observed in the studied subjects 
three weeks prior to the study. 
Serum was collected before treatment and in stable 
euthyrosis state and kept frozen at minus 70∞C until 
used. The serum levels of bone turnover markers: 
osteoclast-derived tartrate-resistant acid phosphatase 
form 5b (TRACP5b) and osteocalcin were determined by 
enzyme-linked immunosorbent assay commercial kits 
produced by Immunodiagnostics Systems Ltd, Boldon, 
UK: TRACP5b (BoneTRAP Assay; sensitivity 0.5 U/l; 
intra-assay precision 6.6%; inter-assay precision 7.2%), 
osteocalcin (N-MID Osteocalcin ELISA; sensitivity 0.5 
ng/ml; intra-assay precision 4.2%; inter-assay preci-
sion 2.2%) and BAP (OstaseBAP; sensitivity 0.5 ng/ml; 
intra-assay precision 4.2%; inter-assay precision 2.2%). 
The serum levels of IL-6 and its soluble receptor (IL-6sR) 
were estimated using R&D Systems, Minneapolis, MN, 
USA commercial kits: IL-6 (Quantikine; sensitivity 0.7 
pg/ml; intra-assay precision 2.0%; inter-assay precision 
3.8%) and IL-6sR (Quantikine; sensitivity 1.5 pg/ml; 
intra-assay precision 2.3%; inter-assay precision 4.7%). 
The statistical significance was estimated by 
Mann-Whitney test. To evaluate relationships between 
variables, Spearman’s test was performed using Sta-
tistica 9.0 for Windows XP (StatSoft, Tulsa, OK, USA). 
Results 
Figure 1 shows medians, interquartiles and total 
ranges of the quotient of serum concentrations of 
TRACP5b (U/L) and osteocalcin (ng/ml) in examined 
groups. TRACP5b/osteocalcin quotient was significantly 
elevated in PostTx females compared to PremTx females 
(p < 0.02). TRACP5b and osteocalcin concentrations ana-
lysed separately were not significantly different between 
groups. All TRACP5b and osteocalcin results in medians 
and interquartiles are given in Table I. There was a posi-
tive correlation between serum TRACP5b and osteocalcin 
in the studied patients (R = 0.45, p < 0.001) (Figure 2). 
Interleukin 6 serum concentration (in pg/ml) is 
shown as median and interquartile values in Figure 3. 
Levels of serum IL-6 values were significantly elevated 
Figure 1. Medians, total and interqurtiles ranges of the quotient 
of serum concentrations of TRACP5b (U/L) and osteocalcin (ng/ml) 
in premenopausal and postmenopausal females as well as in males 
— in thyrotoxicosis and in euthyrosis
Rycina 1. Mediany, zakresy całkowite i międzykwartylowe 
ilorazu stężeń surowiczych TRACP5b (U/L) i osteokalcyny 
(ng/ml) u kobiet przed menopauzą i po niej oraz u mężczyzn 
— w tyreotoksykozie i w eutyreozie
301
Endokrynologia Polska/Polish Journal of Endocrinology 2011; 62 (4)
PR
A
C
E 
O
R
Y
G
IN
A
LN
E
in PostTx: 3.0 (2.14–6.40) and MTx: 2.24 (1.60–5.10) com-
pared to PremTx females: 1.39 (0.96–2.14) (p < 0.01 and 
p < 0.05 respectively). In PremEu, IL-6 serum concentra-
tions were 2.14 (1.20–3.40), in PostEu: 2.4 (1.8–3.8) and 
in MEu: 3.58 (1.60–6.50). Interleukin-6 soluble receptor 
levels were not significantly different in the studied 
groups. In PremTx, IL-6sR level was 45.0 (38.3–52.8), 
in PremEu 47.9 (40.4–54.9), in PostTx 48.6 (42.8-59.1), in 
PostEu 48.4 (40.8–55.8), in MTx 46.1 (41.2–49.2) and in 
MEu 50.9 (41.3–57.5). 
There were significant positive correlations between 
IL-6 and IL-6sR concentrations (R = 0.22, p < 0.05) and 
between IL-6sR and TRACP5b serum levels (R = 0.23, 
p < 0.05).
Discussion
In the present study, significantly elevated TRACP5b/os-
teocalcin quotient in postmenopausal thyrotoxic females 
in comparison with premenopausal women may reflect 
bone resorption overbalance as far as TRACP5b predomi-
nances over osteocalcin-established bone formation fac-
tor. Accelerated bone resorption is accompanied by pro-
portional bone formation increase, as shown by a positive 
correlation between serum TRACP5b and osteocalcin 
values in the present study. Taking this into account, these 
results suggest that bone reconstruction does not keep 
up with accelerated bone resorption in estrogen deficient 
females burdened with thyrotoxicosis. Although thyroid 
hormones are necessary for normal skeletal growth, their 
excess leads to accelerated bone turnover, diminished 
bone density and increased risk of fractures [12, 13]. 
Thyrotoxicosis is accompanied by 12-15% reduction of 
bone mineral density, predominantly of cortical bone, 
and in consequence greatly increases the risk for hip 
fracture, especially in postmenopausal women [14]. Bone 
formation and resorption markers have been shown to 
be elevated in patients with hyperthyroidism and sig-
nificant correlations have been observed between bone 
metabolism indicators and plasma thyroid hormones 
levels [15, 16]. In experimental thyrotoxicosis model bone 
formation markers are additionally increased owing to 
Table I. Medians and interquartile ranges of TRACP5b and osteocalcin serum concentrations in premenopausal 
and postmenopausal females, as well as in males,  in thyrotoxicosis and in euthyrosis
Table I. Mediany i zakresy międzykwartylowe TRACP5b i osteokalcyny surowiczych stężeń u kobiet przed menopauzą 
i po niej oraz u mężczyzn — w tyreotoksykozie i w eutyreozie
PremTx PremEu PostTx PostEu MTx MEu 
TRACP5b 
[U/L] 
1.56
1.24–1.07
1.84
1.46–2.08
1.82
1.4–2.74
2.20
1.68–2.64
2.28
1.32–3.51
1.81
1.25–2.45
Osteocalcin 
[ng/ml] 
23.6
16.0–28.6
20.7
13.3–32.9
15.0
11.9–40.5
25.7
20.6–32.9
19.4
10.1–33.0
13,6
9.0–23.2
Figure 2. Positive correlation between serum TRACP5b 
and osteocalcin (R = 0.45, p < 0.001)
Rycina 2. Dodatnia korelacja pomiędzy stężeniem TRACP5b 
i osteokalcyny (R = 0,45, p < 0,001)
Figure 3. Medians, total and interqurtiles ranges of IL-6 (pg/ml) 
serum concentrations in premenopausal and postmenopausal 
females as well as in males- in thyrotoxicosis and in euthyrosis
Rycina 3. Mediany, zakresy całkowite i międzykwartylowe stężeń 
surowiczych IL-6 (pg/ml) u kobiet przed menopauzą i po niej 
oraz u mężczyzn — w tyreotoksykozie i w eutyreozie
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triiodotyronine, that has been implicated in the enhanced 
production of osteocalcin, alkaline phosphatase and 
I collagen [17]. Osteocalcin is an osteoblast product that 
constitutes the most abundant noncollagenous protein 
present in bone and its serum levels closely correlate with 
histomorphometric parameters of bone formation [18].
The precise mechanism by which thyroid hormones 
regulate osteoblasts and osteoclasts function at a cellular 
level remains unclear. Osteoblasts were suggested to 
mediate the action of triiodotyronine on osteoclastic 
bone resorption releasing osteotrophic cytokines [19, 
20]. The results of the studies carried out on osteob-
last cell cultures have shown that triiodotyronine in-
duces interleukin-6 expression [21, 22]. Our previous 
experimental data suggest that IL-6 plays a crucial 
role in thyrotoxicosis-related disturbances of bone 
turnover in mice, determining the imbalance between 
bone resorption and bone formation caused by excess 
of thyroid hormones, predominantly by inhibition of 
bone formation [10]. However, data from in vivo stu-
dies on the possible role of IL-6 in the pathogenesis of 
disturbances of bone formation thyrotoxicosis-related 
remain equivocal [23, 24].
In the present study levels of serum IL-6 values were 
significantly elevated in estrogen-deficient thyrotoxic 
females (and thyrotoxic men) in comparison to pre-
menopausal women. Moreover significant positive cor-
relations of IL-6sR levels and both: IL-6 and TRACP5b 
serum levels may suggest that IL-6 exerts its effect via 
its soluble receptor and that consequence of this inter-
action is bone resorption augmentation. IL-6 may exert 
its inhibitory effect on bone formation directly through 
gp130-STAT 1/3 signaling or indirectly by influencing 
balance between osteoprotegerin (OPG) and receptor 
activator of nuclear factor B (RANK) and its ligand 
(RANKL) [25, 26].The influence of IL-6 on RANK-RAN-
KL/OPG was suggested to be more powerful effect 
leading to increased bone mass loss [27, 28]. The results 
of our recent experimental study suggest that IL-6 plays 
a key role in stimulation of RANKL-RANK/OPG system 
and this effect is strongly enhanced in conditions of 
accelerated bone turnover such as thyrotoxicosis espe-
cially when accompanied by another factor that enforces 
bone resorption: estrogen depletion [29].
To sum up, the results of the present study suggest 
that interleukin-6 plays a considerable role of in the 
pathogenesis of thyrotoxicosis-related disturbances of 
bone turnover in estrogen-deficient women.
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